Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Arlene Helen Sharpe, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Arlene Sharpe and Gordon Freeman.
Connection Strength

7.612
  1. A new therapeutic strategy for malaria: targeting T cell exhaustion. Nat Immunol. 2012 Jan 19; 13(2):113-5.
    View in: PubMed
    Score: 0.512
  2. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007 Mar; 8(3):239-45.
    View in: PubMed
    Score: 0.365
  3. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006 Oct 02; 203(10):2223-7.
    View in: PubMed
    Score: 0.354
  4. The B7-CD28 superfamily. Nat Rev Immunol. 2002 Feb; 2(2):116-26.
    View in: PubMed
    Score: 0.257
  5. Emerging concepts in PD-1 checkpoint biology. Semin Immunol. 2021 May 15; 101480.
    View in: PubMed
    Score: 0.244
  6. PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J Exp Med. 2021 01 04; 218(1).
    View in: PubMed
    Score: 0.238
  7. The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection. Cell Rep. 2020 06 30; 31(13):107827.
    View in: PubMed
    Score: 0.230
  8. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat Immunol. 2019 10; 20(10):1335-1347.
    View in: PubMed
    Score: 0.218
  9. CD160 Stimulates CD8+ T Cell Responses and Is Required for Optimal Protective Immunity to Listeria monocytogenes. Immunohorizons. 2018 08 27; 2(7):238-250.
    View in: PubMed
    Score: 0.202
  10. Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function. J Immunol. 2018 04 15; 200(8):2592-2602.
    View in: PubMed
    Score: 0.196
  11. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017 04 03; 214(4):895-904.
    View in: PubMed
    Score: 0.183
  12. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016 05 17; 44(5):955-72.
    View in: PubMed
    Score: 0.173
  13. Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol. 2016 05 20; 34:539-73.
    View in: PubMed
    Score: 0.170
  14. PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res. 2015 Dec; 3(12):1308-15.
    View in: PubMed
    Score: 0.167
  15. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
    View in: PubMed
    Score: 0.167
  16. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med. 2015 Sep 21; 212(10):1603-21.
    View in: PubMed
    Score: 0.165
  17. Defective TFH Cell Function and Increased TFR Cells Contribute to Defective Antibody Production in Aging. Cell Rep. 2015 Jul 14; 12(2):163-71.
    View in: PubMed
    Score: 0.163
  18. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014 May 05; 211(5):943-59.
    View in: PubMed
    Score: 0.150
  19. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011 Aug 01; 187(3):1097-105.
    View in: PubMed
    Score: 0.123
  20. Role of PD-1 in regulating acute infections. Curr Opin Immunol. 2010 Jun; 22(3):397-401.
    View in: PubMed
    Score: 0.114
  21. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009 Dec 21; 206(13):3015-29.
    View in: PubMed
    Score: 0.111
  22. Interaction of human PD-L1 and B7-1. Mol Immunol. 2008 Aug; 45(13):3567-72.
    View in: PubMed
    Score: 0.100
  23. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704.
    View in: PubMed
    Score: 0.097
  24. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity. 2007 Dec; 27(6):927-40.
    View in: PubMed
    Score: 0.096
  25. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol. 2007 Oct 15; 179(8):5064-70.
    View in: PubMed
    Score: 0.095
  26. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007 Jul; 27(1):111-22.
    View in: PubMed
    Score: 0.094
  27. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006 Apr 17; 203(4):883-95.
    View in: PubMed
    Score: 0.086
  28. PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. Eur J Immunol. 2006 Jan; 36(1):58-64.
    View in: PubMed
    Score: 0.084
  29. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol. 2005 Dec 01; 175(11):7372-9.
    View in: PubMed
    Score: 0.084
  30. The B7 family revisited. Annu Rev Immunol. 2005; 23:515-48.
    View in: PubMed
    Score: 0.079
  31. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A. 2004 Jul 20; 101(29):10691-6.
    View in: PubMed
    Score: 0.076
  32. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003 Nov; 33(11):3117-26.
    View in: PubMed
    Score: 0.072
  33. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003 Oct; 33(10):2706-16.
    View in: PubMed
    Score: 0.072
  34. Protect the killer: CTLs need defenses against the tumor. Nat Med. 2002 Aug; 8(8):787-9.
    View in: PubMed
    Score: 0.066
  35. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. J Clin Invest. 2001 Apr; 107(7):881-7.
    View in: PubMed
    Score: 0.061
  36. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001 Mar; 2(3):261-8.
    View in: PubMed
    Score: 0.060
  37. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021 02 17; 13(581).
    View in: PubMed
    Score: 0.060
  38. ICOS is critical for CD40-mediated antibody class switching. Nature. 2001 Jan 04; 409(6816):102-5.
    View in: PubMed
    Score: 0.060
  39. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res. 2021 01 01; 27(1):276-287.
    View in: PubMed
    Score: 0.059
  40. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 Mar 01; 27(5):1371-1380.
    View in: PubMed
    Score: 0.059
  41. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol. 2000 Nov 01; 165(9):5035-40.
    View in: PubMed
    Score: 0.059
  42. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
    View in: PubMed
    Score: 0.057
  43. Programmed death ligand 2 - A link between inflammation and bone loss in rheumatoid arthritis. J Transl Autoimmun. 2020; 3:100028.
    View in: PubMed
    Score: 0.055
  44. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity. 1999 Dec; 11(6):689-98.
    View in: PubMed
    Score: 0.055
  45. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proc Natl Acad Sci U S A. 2019 08 20; 116(34):16971-16980.
    View in: PubMed
    Score: 0.054
  46. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
    View in: PubMed
    Score: 0.052
  47. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018 07 26; 174(3):549-563.e19.
    View in: PubMed
    Score: 0.050
  48. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. JCI Insight. 2018 04 19; 3(8).
    View in: PubMed
    Score: 0.049
  49. Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci U S A. 2018 05 01; 115(18):4749-4754.
    View in: PubMed
    Score: 0.049
  50. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017 03 31; 355(6332):1423-1427.
    View in: PubMed
    Score: 0.046
  51. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity. 1997 Mar; 6(3):303-13.
    View in: PubMed
    Score: 0.046
  52. Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand interaction. J Allergy Clin Immunol. 2017 May; 139(5):1468-1477.e2.
    View in: PubMed
    Score: 0.044
  53. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016 09 15; 537(7620):417-421.
    View in: PubMed
    Score: 0.044
  54. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016 07 01; 126(7):2642-60.
    View in: PubMed
    Score: 0.043
  55. Differential expression of alternate mB7-2 transcripts. J Immunol. 1995 Dec 15; 155(12):5490-7.
    View in: PubMed
    Score: 0.042
  56. ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity. Immunity. 2015 Mar 17; 42(3):538-51.
    View in: PubMed
    Score: 0.040
  57. Characterization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16, band B5. J Immunol. 1994 Dec 01; 153(11):5038-48.
    View in: PubMed
    Score: 0.039
  58. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014 Nov 27; 515(7528):577-81.
    View in: PubMed
    Score: 0.039
  59. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med. 2014 Aug 25; 211(9):1905-18.
    View in: PubMed
    Score: 0.038
  60. A negative regulatory function of B7 revealed in B7-1 transgenic mice. Immunity. 1994 Aug; 1(5):415-21.
    View in: PubMed
    Score: 0.038
  61. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
    View in: PubMed
    Score: 0.037
  62. Inclusion of CD80 in HSV targets the recombinant virus to PD-L1 on DCs and allows productive infection and robust immune responses. PLoS One. 2014; 9(1):e87617.
    View in: PubMed
    Score: 0.037
  63. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013 Oct 24; 122(17):3062-73.
    View in: PubMed
    Score: 0.036
  64. DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8? T cells independently of PD-1 and PD-L1. Int Immunol. 2013 Nov; 25(11):651-60.
    View in: PubMed
    Score: 0.036
  65. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A. 2013 Sep 10; 110(37):15001-6.
    View in: PubMed
    Score: 0.036
  66. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci U S A. 2011 Dec 27; 108(52):21182-7.
    View in: PubMed
    Score: 0.032
  67. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol. 2011 Aug 01; 187(3):1113-9.
    View in: PubMed
    Score: 0.031
  68. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol. 2011 May; 31(5):1100-7.
    View in: PubMed
    Score: 0.030
  69. The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. J Virol. 2011 May; 85(9):4184-97.
    View in: PubMed
    Score: 0.030
  70. Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation. Invest Ophthalmol Vis Sci. 2010 Jul; 51(7):3418-23.
    View in: PubMed
    Score: 0.028
  71. Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells. Invest Ophthalmol Vis Sci. 2009 Oct; 50(10):4941-8.
    View in: PubMed
    Score: 0.027
  72. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol. 2009 Feb 15; 182(4):2102-12.
    View in: PubMed
    Score: 0.026
  73. Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. Ocul Immunol Inflamm. 2009 Jan-Feb; 17(1):47-55.
    View in: PubMed
    Score: 0.026
  74. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20428-33.
    View in: PubMed
    Score: 0.026
  75. ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol. 2008 Apr 15; 180(8):5448-56.
    View in: PubMed
    Score: 0.025
  76. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med. 2008 Mar 17; 205(3):543-55.
    View in: PubMed
    Score: 0.024
  77. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 2007 Oct 30; 116(18):2062-71.
    View in: PubMed
    Score: 0.024
  78. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci U S A. 2007 Sep 25; 104(39):15430-5.
    View in: PubMed
    Score: 0.024
  79. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol. 2007 Sep 15; 179(6):3672-9.
    View in: PubMed
    Score: 0.024
  80. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006 Feb 09; 439(7077):682-7.
    View in: PubMed
    Score: 0.021
  81. Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo. J Immunol. 2005 Sep 01; 175(5):3133-9.
    View in: PubMed
    Score: 0.021
  82. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood. 2005 Apr 15; 105(8):3372-80.
    View in: PubMed
    Score: 0.020
  83. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity. 2004 May; 20(5):563-75.
    View in: PubMed
    Score: 0.019
  84. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest. 2003 Jul; 112(2):234-43.
    View in: PubMed
    Score: 0.018
  85. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med. 2002 Sep; 8(9):1024-32.
    View in: PubMed
    Score: 0.017
  86. Intercellular adhesion molecule 1 is critical for activation of CD28-deficient T cells. J Immunol. 2000 Dec 01; 165(11):6091-8.
    View in: PubMed
    Score: 0.015
  87. CD48-deficient mice have a pronounced defect in CD4(+) T cell activation. Proc Natl Acad Sci U S A. 1999 Feb 02; 96(3):1019-23.
    View in: PubMed
    Score: 0.013
  88. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. J Immunol. 1997 Mar 01; 158(5):2025-34.
    View in: PubMed
    Score: 0.011
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.